MetaCap

Acrivon Therapeutics (ACRV) vs Nomad Power Solutions (NMAD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nomad Power Solutions (NMAD) has outperformed Acrivon Therapeutics (ACRV) over the past year, losing 40.6% versus a loss of 50.0%. Acrivon Therapeutics is the larger company by market cap ($49.3 million vs $47.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRV-50.00%NMAD-40.60%
+93%+18%-57%
Nov 21, 20251 yearNov 20, 2026
ACRV-92.71%NMAD-55.86%
+117%+7%-103%
Nov 14, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRV versus NMAD key metrics
MetricACRVNMAD
Share price$1.15$2.56
Market cap$49.35M$47.15M
1-day change-17.86%+13.53%
YTD return-52.28%-34.86%
1-year return-50.00%-40.60%
5-year return—-84.58%
EPS (TTM)$-1.82$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-77.91M$-6.08M
52-week high$3.56$8.38
52-week low$0.9709$2.13
Distance from 52-week high-67.70%-69.45%
Analyst consensusnone—
Avg. price target upside+900.00%—
Average volume275.69K228.96K
Shares outstanding42.91M18.42M
Employees74—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Acrivon Therapeutics

ACRV stock →

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Nomad Power Solutions

NMAD stock →

NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.

Health Care · Biotechnology: Pharmaceutical Preparations

ACRV vs NMAD FAQ

Which is bigger, Acrivon Therapeutics or Nomad Power Solutions?

Acrivon Therapeutics (ACRV) is larger, with a market capitalization of $49.35M compared with $47.15M for Nomad Power Solutions (NMAD).

Which stock has performed better over the past year, ACRV or NMAD?

NMAD returned -40.60% over the past 12 months, compared with -50.00% for ACRV (price return, excluding dividends). Past performance does not predict future results.

Are Acrivon Therapeutics and Nomad Power Solutions in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons